Brief: Agios Provides Update On Phase 2B Trial Of Tebapivat In Lower-Risk Myelodysplastic Syndromes

Agios Pharmaceuticals

29/05/2026 13:32

May 29 (Reuters) - Agios Pharmaceuticals Inc AGIO.O:
AGIOS PROVIDES UPDATE ON PHASE 2B TRIAL OF TEBAPIVAT IN LOWER-RISK MYELODYSPLASTIC SYNDROMES
AGIOS PHARMACEUTICALS - WILL NOT ADVANCE TEBAPIVAT IN LOWER-RISK MYELODYSPLASTIC SYNDROMES
AGIOS PHARMACEUTICALS - PHASE 2B TRIAL RESULTS FOR TEBAPIVAT IN LR-MDS DID NOT MEET PREDEFINED THRESHOLD
AGIOS PHARMACEUTICALS - TEBAPIVAT WELL TOLERATED WITH NO NEW SAFETY SIGNALS IDENTIFIED
AGIOS PHARMACEUTICALS - TEBAPIVAT PHASE 2 TRIAL IN SICKLE CELL DISEASE TOPLINE DATA EXPECTED SECOND HALF 2026
Source text: ID:nGNX3DPktn
Further company coverage: AGIO.O

 ((Reuters.Briefs@thomsonreuters.com;))